Results 21 to 30 of about 56,993 (185)

Sevelamer Attenuates Bioprosthetic Heart Valve Calcification

Frontiers in Cardiovascular Medicine, 2021
Objective: Sevelamer hydrochloride is a phosphate binder used to treat hyperphosphatemia in chronic kidney disease (CKD) patients that can reduce valvular and vascular calcification. The aim of this study was to examine the effects of sevelamer treatment
Zhen Meng, Zhe Li, Erli Zhang, Li Zhang, Qingrong Liu, Yongjian Wu   +5 more
doaj   +1 more source

New Conclusions Regarding Comparison of Sevelamer and Calcium-Based Phosphate Binders in Coronary-Artery Calcification for Dialysis Patients: A Meta-Analysis of Randomized Controlled Trials. [PDF]

PLoS ONE, 2015
Sevelamer hydrochloride is used widely, but its impact upon cardiovascular calcification, cardiovascular mortality, all-cause mortality and hospitalization is not known.Primary outcome was cardiovascular calcification (coronary artery calcification ...
Caixia Wang, Xun Liu, Yongming Zhou, Shaomin Li, Yanbing Chen, Yanni Wang, Tanqi Lou   +6 more
doaj   +1 more source

Nanocarrier‐Based Drug Delivery Systems using Microfluidic‐Assisted Techniques

Advanced NanoBiomed Research, Volume 3, Issue 11, November 2023., 2023
This research reviews the progress of nanocarrier‐facilitated microfluidic‐based and organ‐on‐a‐chip‐modeled microfluidic nanodrug delivery systems in clinical translation. Different factors and challenges that hinder a drug delivery system, from its conception to experimental validation and start‐up investment to commercialization for clinical ...
Md. Kowsar Alam
wiley   +1 more source

Bile Acid Sequestrant, Sevelamer Ameliorates Hepatic Fibrosis with Reduced Overload of Endogenous Lipopolysaccharide in Experimental Nonalcoholic Steatohepatitis

Microorganisms, 2020
Despite the use of various pharmacotherapeutic strategies, fibrosis due to nonalcoholic steatohepatitis (NASH) remains an unsatisfied clinical issue. We investigated the effect of sevelamer, a hydrophilic bile acid sequestrant, on hepatic fibrosis in a ...
Yuki Tsuji, Kosuke Kaji, Mitsuteru Kitade, Daisuke Kaya, Koh Kitagawa, Takahiro Ozutsumi, Yukihisa Fujinaga, Hiroaki Takaya, Hideto Kawaratani, Tadashi Namisaki, Kei Moriya, Takemi Akahane, Hitoshi Yoshiji   +12 more
doaj   +1 more source

Pediatric dosing for locally acting drugs in submissions to the U.S. Food and Drug Administration between 2002 and 2020

Clinical and Translational Science, Volume 16, Issue 10, Page 2046-2057, October 2023., 2023
Abstract Deriving pediatric doses for locally acting drugs (LADs) presents a unique challenge because limited systemic exposure hinders commonly used approaches such as pharmacokinetic matching to adults. This study systematically evaluated drug development practices used for pediatric dose selection of LADs approved by the U.S.
Gelareh A. Abulwerdi, Anuradha Ramamoorthy, Edward Bashaw, Gilbert J. Burckart, Rajanikanth Madabushi, Elimika Pfuma Fletcher   +5 more
wiley   +1 more source

Influence of medications on thyroid function in dogs: An update

Journal of Veterinary Internal Medicine, Volume 37, Issue 5, Page 1626-1640, September/October 2023., 2023
Abstract Erroneous thyroid function test results can occur because of drugs that alter thyroid hormone physiology in one or more aspects, including synthesis, secretion, distribution, and metabolism. Research since publication of the last review in the Journal of Veterinary Internal Medicine (JVIM) 20 years ago has evaluated the effects of amiodarone ...
Timothy A. Bolton, David L. Panciera
wiley   +1 more source

Cyclodextrin Polymers Functionalized with Histidine and Carcinine as Chelating Therapeutics for Copper Dyshomeostasis

ChemMedChem, Volume 18, Issue 13, July 3, 2023., 2023
We derivatized cross‐linked cyclodextrin polymers with histidine or carcinine moieties. We found that amylases do not hydrolyze cyclodextrin polymers. The new polymers can form copper(II) complexes and may act as nanochelators to counteract copper(II) dyshomeostasis‐related diseases.
Noemi Bognanni, Francesco Bellia, Graziella Vecchio   +2 more
wiley   +1 more source

Correlation of Serum FGF23 and Chronic Kidney Disease‐Mineral and Bone Abnormality Markers With Cardiac Structure Changes in Maintenance Hemodialysis Patients

Evidence-Based Complementary and Alternative Medicine, Volume 2023, Issue 1, 2023., 2023
Background. CKD‐MBD is a mineral and bone metabolism syndrome caused by chronic kidney disease. FGF23 is an important factor regulating phosphorus and is the main influencer in the CKD‐MBD process. In this study, we observed the correlation among serum FGF23 and calcium, phosphorus and parathyroid hormone, and the correlation between FGF23 levels and ...
Dewang Zeng, Aiyun Zha, Ying Lei, Zongchao Yu, Rui Cao, Ling Li, Zhuoheng Song, Weilong Li, Yunyi Li, Haiping Liu, Shaoxing Huang, Xiangnan Dong, Bernhard Krämer, Berthold Hocher, Lianghong Yin, Chen Yun, Stanislao Morgera, Baozhang Guan, Yu Meng, Fanna Liu, Bo Hu, Shaodong Luan, Shuli Yang   +22 more
wiley   +1 more source

Treatment of anemia associated with chronic kidney disease with the HIF prolyl hydroxylase inhibitor enarodustat: A review of the evidence

Therapeutic Apheresis and Dialysis, Volume 26, Issue 4, Page 679-693, August 2022., 2022
Abstract Enarodustat, a newly developed hypoxia‐inducible factor prolyl hydroxylase inhibitor, is used in clinical practice in Japan. Several clinical studies showed that enarodustat corrected and maintained hemoglobin (Hb) levels by stimulating endogenous erythropoietin production and improving iron utilization in anemic patients with chronic kidney ...
Ryo Fujikawa, Yuji Nagao, Masaki Fujioka, Tadao Akizawa   +3 more
wiley   +1 more source

Effect of Sevelamer on Calciprotein Particles in Hemodialysis Patients: The Sevelamer Versus Calcium to Reduce Fetuin-A-Containing Calciprotein Particles in Dialysis (SCaRF) Randomized Controlled Trial

Kidney International Reports, 2020
Introduction: Calciprotein particles (CPPs) are potentially modifiable mediators of phosphate toxicity in patients with kidney disease. We compared the effects of calcium carbonate (CC) and the non–calcium-based phosphate binder sevelamer on CPP levels ...
Edward R. Smith, Fei Fei M. Pan, Tim D. Hewitson, Nigel D. Toussaint, Stephen G. Holt   +4 more
doaj   +1 more source